Clinical trial NCT06117774: Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Limited Stage Small Cell Lung Cancer
Small Cell Lung Cancer
Keywords: Limited Stage Small Cell Lung Cancer
Small Cell Lung Cancer
LS SCLC
SCLC
AMG 757
Tarlatamab
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2023-11-07
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS).


Eligibility criteria: Inclusion Criteria: -Participants are eligible to be included in the study only if all of the following criteria apply:

* Participant has provided informed consent prior to initiation of any study specific activities/procedures.
* Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years).
* Histologically or cytologically confirmed small-cell lung cancer (SCLC).
* Diagnosed and treated for LS-SCLC with concurrent chemotherapy and radiotherapy.
* Has completed chemoradiotherapy without progression per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1.) (ie, achieved complete response \[CR\], partial response \[PR\], or stable disease \[SD\]).
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.
* Minimum life expectancy of 12 weeks.
* Adequate organ function.
* Toxicities attributed to concurrent chemoradiotherapy resolved to grade ≤ 1, unless otherwise specified. Excluding alopecia or fatigue.

Exclusion Criteria: -Participants are excluded from the study if any of the following criteria apply:

Disease Related

* Extensive-stage SCLC (ES-SCLC).
* Any previous diagnosis of transformed non-small-cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation positive NSCLC that has transformed to SCLC, or mixed SCLC NSCLC histology.
* Evidence of interstitial lung disease or active, non-infectious pneumonitis. Other Medical Conditions
* History of other malignancy within the past 2 years, with certain exceptions.
* History of solid organ transplantation.
* Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association \> class II) within 6 months prior to first dose of study treatment.
* History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months prior to first dose of study treatment.
* Exclusion of human immunodeficiency virus (HIV) and/or hepatitis infection based on criteria per protocol.
* Participant with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment.

Prior/Concomitant Therapy

* Received sequential chemotherapy and thoracic radiotherapy (no overlap of thoracic radiotherapy with chemotherapy) during chemoradiation.
* Prior therapy with any selective inhibitor of the delta-like ligand 3 (DLL3) pathway.
* Prior history of severe or life-threatening events from any immune-mediated therapy.
* Receiving another anti-cancer therapy. Adjuvant hormonal therapy for resected breast cancer is permitted.
* Receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollment.
* Major surgical procedures within 28 days prior to first dose of study treatment.
* Treatment with live virus, including live-attenuated vaccination, within 14 days prior to the first dose of study treatment. Inactive vaccines and live viral non-replicating vaccines within 3 days prior to first dose of study treatment.

Prior/Concurrent Clinical Study Experience

• Treatment in an alternative investigational trial within 28 days prior to enrollment.

Other Exclusions

* Female participants of childbearing potential unwilling to use protocol specified method of contraception during treatment and for an additional 60 days after the last dose of study treatment.
* Female participants who are breastfeeding or who plan to breastfeed while on study through 60 days after the last dose of study treatment.
* Female participants planning to become pregnant or donate eggs while on study through 60 days after the last dose of study treatment.
* Female participants of childbearing potential with a positive pregnancy test assessed at screening by a highly sensitive serum pregnancy test.
* Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 60 days after the last dose of study treatment.
* Male participants with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 60 days after the last dose of study treatment.
* Male participants unwilling to abstain from donating sperm during treatment and for an additional 60 days after the last dose of study treatment.
* Participant has known sensitivity to any of the products or components to be administered during dosing.
* Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the participant and investigator's knowledge.
* History or evidence of any other clinically significant disorder, condition, or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures or completion.

Primary outcomes:
measure: PFS as Determined by Blinded Independent Central Review (BICR)
timeFrame: Up to approximately 6 years
Secondary outcomes:
measure: Overall Survival (OS) Over the Whole Trial
timeFrame: Up to approximately 6 years
measure: PFS Determined by Investigator Assessment
timeFrame: Up to approximately 6 years
measure: Objective Response (OR) Rate
timeFrame: Up to approximately 6 years
measure: Disease Control (DC) Rate
timeFrame: Up to approximately 6 years
measure: Duration of Response (DOR)
timeFrame: Up to approximately 6 years
measure: PFS at 6 months, 1 year, 2 years
timeFrame: 6 months, 1 year, 2 years
measure: OS at 6 months, 1 year, 2 years, 3 years
timeFrame: 6 months, 1 year, 2 years, 3 years
measure: Time to Progression (TTP)
timeFrame: Up to approximately 6 years
measure: Number of Participants with Treatment-emergent Adverse Events (TEAEs)
timeFrame: Up to approximately 6 years
measure: Serum Concentration of Tarlatamab
timeFrame: Up to approximately 4 months
measure: Incidence of Anti-tarlatamab Antibody Formation
timeFrame: Up to approximately 1 year
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Valkyrie Clinical Trials
state: California
city: Santa Monica
country: United States
facility: University of California Los Angeles
state: California
city: New Haven
country: United States
facility: Yale New Haven Hospital
state: Connecticut
city: Plantation
country: United States
facility: Boca Raton Clinical Research Global South Florida
state: Florida
city: Louisville
country: United States
facility: University of Louisville James Graham Brown Cancer Center
state: Kentucky
city: Baton Rouge
country: United States
facility: Our Lady of the Lake Cancer Institute
state: Louisiana
city: Morristown
country: United States
facility: Morristown Medical Center
state: New Jersey
city: Bronx
country: United States
facility: Montefiore Einstein Center for Cancer Care
state: New York
city: New York
country: United States
facility: New York University Grossman School of Medicine and New York University Langone Hospitals
state: New York
city: New York
country: United States
facility: Perlmutter Cancer Center at New York University Langone Hospital - Long Island
state: New York
city: Pinehurst
country: United States
facility: FirstHealth Cancer Center
state: North Carolina
city: Allentown
country: United States
facility: Lehigh Valley Health Network
state: Pennsylvania
city: Easton
country: United States
facility: Spokenword Clinical Trials
state: Pennsylvania
city: The Woodlands
country: United States
facility: Renovatio Clinical
state: Texas
city: The Woodlands
country: United States
facility: US Oncology Research Investigational Products Center
state: Texas
city: Charlottesville
country: United States
facility: University of Virginia Health System
state: Virginia
city: Fairfax
country: United States
facility: Virginia Cancer Specialists, PC
state: Virginia
city: Morgantown
country: United States
facility: West Virginia University Health Sciences Center
state: West Virginia
city: Ciudad Autonoma de Buenos Aires
country: Argentina
facility: Fundacion Respirar
state: Buenos Aires
city: La Plata
country: Argentina
facility: Hospital Italiano de La Plata
state: Buenos Aires
city: Pilar
country: Argentina
facility: Hospital Universitario Austral
state: Buenos Aires
city: Cordoba
country: Argentina
facility: Instituto Oncologico de Cordoba Ionc Fundacion Richardet Longo
state: Córdoba
city: Caba
country: Argentina
facility: Hospital Aleman Buenos Aires
state: Distrito Federal
city: Viedma
country: Argentina
facility: Clinica Viedma
state: Río Negro
city: San Miguel de Tucuman
country: Argentina
facility: Sanatorio 9 de Julio Cice 9 de Julio
state: Tucuman
city: Buenos Aires
country: Argentina
facility: Instituto Argentino de Diagnóstico y Tratamiento
city: Port Macquarie
country: Australia
facility: Port Macquarie Base Hospital
state: New South Wales
city: Westmead
country: Australia
facility: Westmead Hospital
state: New South Wales
city: Bedford Park
country: Australia
facility: Flinders Medical Centre
state: South Australia
city: Clayton
country: Australia
facility: Monash Medical Centre
state: Victoria
city: Murdoch
country: Australia
facility: Fiona Stanley Hospital
state: Western Australia
city: Graz
country: Austria
facility: Medizinische Universitaet Graz
city: Wien
country: Austria
facility: Universitaetsklinikum Allgemeines Krankenhaus Wien
city: Brussels
country: Belgium
facility: Institut Jules Bordet
city: Gent
country: Belgium
facility: Universitair Ziekenhuis Gent
city: Brasilia
country: Brazil
facility: Oncoclinicas Onco Vida Distrito Federal
state: Distrito Federal
city: Vitoria
country: Brazil
facility: Hospital Santa Rita
state: Espírito Santo
city: Curitba
country: Brazil
facility: Liga Paranaense do Combate ao Cancer - Hospital Erasto Gaertner
state: Paraná
city: Londrina
country: Brazil
facility: Londrina Cancer Hospital
state: Paraná
city: Natal
country: Brazil
facility: Liga Norte-Riograndense Contra O Cancer
state: Rio Grande Do Norte
city: Porto Alegre
country: Brazil
facility: Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul
state: Rio Grande Do Sul
city: Porto Alegre
country: Brazil
facility: Cipo - Centro Integrado de Pesquisa em Oncologia
state: Rio Grande Do Sul
city: Santa Cruz do Sul
country: Brazil
facility: Centro de pesquisa em oncologia Hospital Ana Nery
state: Rio Grande Do Sul
city: Blumenau
country: Brazil
facility: Centro Catarinense de Pesquisa LTDA
state: Santa Catarina
city: Barretos
country: Brazil
facility: Fundacao Pio 12 Hospital de Amor de Barretos
state: São Paulo
city: Jau
country: Brazil
facility: Fundacao Amaral Carvalho
state: São Paulo
city: Santo Andre
country: Brazil
facility: Cepho
state: São Paulo
city: Rio de Janeiro
country: Brazil
facility: Instituto Dor de Pesquisa e Ensino
city: São Paulo
country: Brazil
facility: Instituto do Cancer do Estado de Sao Paulo Octavio Frias de Oliveira Icesp
city: Panagyurishte
country: Bulgaria
facility: Multiprofile Hospital for Active Treatment - Uni Hospital OOD
city: Plovdiv
country: Bulgaria
facility: Complex Oncology Center Plovdiv EOOD
city: Shumen
country: Bulgaria
facility: Complex Oncology Center Shumen EOOD
city: Sofia
country: Bulgaria
facility: University Multiprofile Hospital for Active Treatment Sofiamed OOD
city: Sofia
country: Bulgaria
facility: University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD
city: Sofia
country: Bulgaria
facility: Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia
city: Sofia
country: Bulgaria
facility: Multiprofile Hospital for Active Treatment Serdika EOOD
city: Beijing
country: China
facility: Beijing Cancer Hospital
state: Beijing
city: Chongqing
country: China
facility: Chongqing University Cancer Hospital
state: Chongqing
city: Fuzhou
country: China
facility: Fujian Cancer Hospital
state: Fujian
city: Fuzhou
country: China
facility: Mengchao Hepatobiliary Hospital of Fujian Medical University
state: Fujian
city: Guangzhou
country: China
facility: Sun Yat-Sen University Cancer Center
state: Guangdong
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
state: Henan
city: Wuhan
country: China
facility: Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
state: Hubei
city: Wuhan
country: China
facility: Renmin Hospital of Wuhan University
state: Hubei
city: Wuhan
country: China
facility: Hubei Cancer Hospital
state: Hubei
city: Changsha
country: China
facility: Hunan Cancer Hospital
state: Hunan
city: Yangzhou
country: China
facility: Northern Jiangsu Peoples hospital
state: Jiangsu
city: Nanchang
country: China
facility: Jiangxi Cancer hospital
state: Jiangxi
city: Changchun
country: China
facility: The First Bethune Hospital of Jilin University
state: Jilin
city: Jinan
country: China
facility: Cancer Hospital of Shandong First Medical University
state: Shandong
city: Qingdao
country: China
facility: Qingdao Municipal Hospital
state: Shandong
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
state: Shanghai
city: Taiyuan
country: China
facility: Shanxi Provincial Cancer Hospital
state: Shanxi
city: Taiyuan
country: China
facility: Shanxi Bethune Hospital
state: Shanxi
city: Tianjin
country: China
facility: Tianjin Cancer Hospital
state: Tianjin
city: Urumqi
country: China
facility: The First Affiliated Hospital of Xinjiang Medical University
state: Xinjiang
city: Hangzhou
country: China
facility: The Second Affiliated Hospital of Zhejiang University School of Medicine
state: Zhejiang
city: Ningbo
country: China
facility: Ningbo Medical Center Lihuili Hospital
state: Zhejiang
city: Taizhou
country: China
facility: Zhejiang Taizhou Hospital
state: Zhejiang
city: Bogota
country: Colombia
facility: Centro de Tratamiento e Investigación sobre Cancer Luis Carlos Sarmiento Angulo Ctic
state: Cundinamarca
city: Monteria
country: Colombia
facility: Instituto Medico de Alta Tecnologia sas - Imat sas
state: Córdoba
city: Pereira
country: Colombia
facility: Oncologos del Occidente SAS
state: Risaralda
city: Bucaramanga
country: Colombia
facility: Fundacion cardiovascular de Colombia
state: Santander
city: Lille
country: France
facility: Centre Hospitalier Régional Universitaire de Lille - Institut Coeur Poumon
city: Marseille Cedex 20
country: France
facility: Centre Hospitalier Universitaire Nord
city: Nice Cedex 01
country: France
facility: Centre Hospitalier Universitaire de Nice - Hopital Pasteur
city: Paris
country: France
facility: Hopital Bichat Claude Bernard
city: Villefranche Sur Saone Cedex
country: France
facility: Hopital Nord Ouest Villefranche sur Saone
city: Essen
country: Germany
facility: Universitaetsklinikum Essen
city: Goettingen
country: Germany
facility: Universitaetsmedizin Goettingen
city: Wuerzburg
country: Germany
facility: Universitaetsklinikum Wuerzburg
city: Athens
country: Greece
facility: Agios Savvas Anticancer Hospital
city: Athens
country: Greece
facility: Henry Dunant Hospital Center
city: Athens
country: Greece
facility: Sotiria General Hospital
city: Athens
country: Greece
facility: Attikon University Hospital
city: Athens
country: Greece
facility: Metropolitan Hospital
city: Thessaloniki
country: Greece
facility: Saint Lukes Hospital SA
city: Thessaloniki
country: Greece
facility: European Interbalkan Medical Center
city: Hong Kong
country: Hong Kong
facility: Queen Mary Hospital, The University of Hong Kong
city: Shatin, New Territories
country: Hong Kong
facility: Prince of Wales Hospital, Chinese University of Hong Kong
city: Aviano PN
country: Italy
facility: Centro di Riferimento Oncologico di Aviano
city: Milano
country: Italy
facility: Fondazione IRCCS Istituto Nazionale dei Tumori
city: Milano
country: Italy
facility: IRCCS Istituto Oncologico Europeo
city: Orbassano
country: Italy
facility: Azienda Ospedaliera Universitaria San Luigi Gonzaga
city: Padova
country: Italy
facility: Istituto Oncologico Veneto IRCCS
city: Perugia
country: Italy
facility: Azienda Ospedaliera di Perugia Ospedale Santa Maria della Misericordia
city: Pisa
country: Italy
facility: Azienda Ospedaliero Universitaria Pisana
city: Reggio Emilia
country: Italy
facility: Azienda Unita Sanitaria Locale di Reggio Emilia Arcispedale Santa Maria Nuova
city: Rozzano MI
country: Italy
facility: IRCCS Istituto Clinico Humanitas
city: Statte
country: Italy
facility: Ospedale San Giuseppe Moscati
city: Nagoya-shi
country: Japan
facility: National Hospital Organization Nagoya Medical Center
state: Aichi
city: Kashiwa-shi
country: Japan
facility: National Cancer Center Hospital East
state: Chiba
city: Matsuyama-shi
country: Japan
facility: National Hospital Organization Shikoku Cancer Center
state: Ehime
city: Kurume-shi
country: Japan
facility: Kurume University Hospital
state: Fukuoka
city: Sapporo-shi
country: Japan
facility: National Hospital Organization Hokkaido Cancer Center
state: Hokkaido
city: Yokohama-shi
country: Japan
facility: Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center
state: Kanagawa
city: Sendai-shi
country: Japan
facility: Sendai Kousei Hospital
state: Miyagi
city: Niigata-shi
country: Japan
facility: Niigata Cancer Center Hospital
state: Niigata
city: Okayama-shi
country: Japan
facility: Okayama University Hospital
state: Okayama
city: Hirakata-shi
country: Japan
facility: Kansai Medical University Hospital
state: Osaka
city: Osaka-shi
country: Japan
facility: Osaka International Cancer Institute
state: Osaka
city: Osakasayama-shi
country: Japan
facility: Kindai University Hospital
state: Osaka
city: Hidaka-Shi
country: Japan
facility: Saitama Medical University International Medical Center
state: Saitama
city: Kitaadachi-gun
country: Japan
facility: Saitama Cancer Center
state: Saitama
city: Sunto-gun
country: Japan
facility: Shizuoka Cancer Center
state: Shizuoka
city: Shimotsuga-gun
country: Japan
facility: Dokkyo Medical University Hospital
state: Tochigi
city: Bunkyo-ku
country: Japan
facility: Juntendo University Hospital
state: Tokyo
city: Chuo-ku
country: Japan
facility: National Cancer Center Hospital
state: Tokyo
city: Koto-ku
country: Japan
facility: The Cancer Institute Hospital of Japanese Foundation for Cancer Research
state: Tokyo
city: Wakayama
country: Japan
facility: Wakayama Medical University Hospital
city: Cheongju Chungbuk
country: Korea, Republic of
facility: Chungbuk National University Hospital
city: Goyang-si Gyeonggi-do
country: Korea, Republic of
facility: National Cancer Center
city: Incheon
country: Korea, Republic of
facility: Gachon University Gil Hospital
city: Jinju-si
country: Korea, Republic of
facility: Gyeongsang National University Hospital
city: Seongnam-si, Gyeonggi-do
country: Korea, Republic of
facility: Cha Bundang Medical Center, Cha University
city: Seongnam-si, Gyeonggi-do
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital Yonsei University Health System
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Ciudad de México
country: Mexico
facility: Oncare
state: Distrito Federal
city: Cuauhtemoc
country: Mexico
facility: Centro Oncologico Personalizado
state: Distrito Federal
city: Toluca
country: Mexico
facility: Phylasis Clinicas Research Toluca
city: Bialystok
country: Poland
facility: Uniwersytecki Szpital Kliniczny w Bialymstoku
city: Bystra
country: Poland
facility: Centrum Pulmonologii i Torakochirurgii w Bystrej
city: Gdansk
country: Poland
facility: Uniwersyteckie Centrum Kliniczne
city: Lublin
country: Poland
facility: Uniwerystecki Szpital Kliniczny Nr 4 w Lublinie
city: Poznan
country: Poland
facility: Wielkopolskie Centrum Pulmonologii i Torakochirurgii imienia Eugenii i Janusza Zeylandow
city: Prabuty
country: Poland
facility: Szpital Specjalistyczny w Prabutach Spolka z Ograniczoną Odpowiedzialnoscia
city: Przemysl
country: Poland
facility: Wojewodzki Szpital im Sw Ojca Pio w Przemyslu
city: Warszawa
country: Poland
facility: Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy
city: Braga
country: Portugal
facility: Unidade Local de Saude de Braga, EPE
city: Lisboa
country: Portugal
facility: Hospital da Luz, SA
city: Porto
country: Portugal
facility: Hospital Cuf porto
city: Bucuresti
country: Romania
facility: Institutul Oncologic, Prof Dr Alexandru Trestioreanu
city: Cluj Napoca
country: Romania
facility: Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca
city: Craiova
country: Romania
facility: Centrul de Oncologie Sf Nectarie SRL
city: Iasi
country: Romania
facility: Institutul Regional de Oncologie Iasi
city: Ploiesti
country: Romania
facility: Spitalul Municipal Ploiesti
city: Timisoara
country: Romania
facility: SC Oncomed SRL
city: Singapore
country: Singapore
facility: National Cancer Centre Singapore
city: Singapore
country: Singapore
facility: Icon - Mount Alvernia
city: Malaga
country: Spain
facility: Hospital Regional Universitario de Malaga
state: Andalucía
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen del Rocio
state: Andalucía
city: Las Palmas de Gran Canaria
country: Spain
facility: Hospital Universitario Insular de Gran Canaria
state: Canarias
city: Badalona
country: Spain
facility: Institut Catala d Oncologia Badalona Hospital Universitari Germans Trias i Pujol
state: Cataluña
city: Barcelona
country: Spain
facility: Hospital del Mar
state: Cataluña
city: Barcelona
country: Spain
facility: Hospital Universitari Vall d Hebron
state: Cataluña
city: Barcelona
country: Spain
facility: Hospital Clinic i Provincial de Barcelona
state: Cataluña
city: Barcelona
country: Spain
facility: Hospital de la Santa Creu i Sant Pau
state: Cataluña
city: Valencia
country: Spain
facility: Instituto Valenciano de Oncologia
state: Comunidad Valenciana
city: Santiago de Compostela
country: Spain
facility: Hospital Clinico Universitario de Santiago
state: Galicia
city: Majadahonda
country: Spain
facility: Hospital Universitario Puerta de Hierro Majadahonda
state: Madrid
city: Pamplona
country: Spain
facility: Clinica Universidad de Navarra
state: Navarra
city: Madrid
country: Spain
facility: Hospital General Universitario Gregorio Maranon
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre
city: Goteborg
country: Sweden
facility: Sahlgrenska Universitetssjukhuset
city: Umea
country: Sweden
facility: Norrlands Universitetssjukhus
city: Baden
country: Switzerland
facility: Kantonsspital Baden
city: Basel
country: Switzerland
facility: Universitaetsspital Basel
city: Mendrisio
country: Switzerland
facility: Ospedale Regionale di Bellinzona e Vali
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University Chung-Ho Memorial Hospital
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
city: Ankara
country: Turkey
facility: Memorial Ankara Hastanesi
city: Ankara
country: Turkey
facility: Ankara Bilkent Sehir Hastanesi
city: Istanbul
country: Turkey
facility: Bagcilar Medipol Mega Universite Hastanesi
city: Istanbul
country: Turkey
facility: Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi
city: Istanbul
country: Turkey
facility: Marmara Universitesi Tip Fakultesi Hastanesi
city: Izmir
country: Turkey
facility: Izmir Ekonomi Universitesi Medical Point Hastanesi
city: Kocaeli
country: Turkey
facility: Kocaeli Universitesi Tip Fakultesi Hastanesi
city: Mersin
country: Turkey
facility: Medical Park Seyhan Hastanesi
city: Samsun
country: Turkey
facility: Ondokuz Mayis Universitesi Tip Fakultesi Hastanesi
city: London
country: United Kingdom
facility: Guys Hospital
city: Manchester
country: United Kingdom
facility: Christie Hospital
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References: